Skip to main content

Table 1 Summary of clinicopathological features and follow up of patients with pancreatic cancer

From: Epigenetic silencing of AATK in acinar to ductal metaplasia in murine model of pancreatic cancer

Characteristics Number (%) AATK expression P
Low High
Age
< 65 41 (49.4) 32 (78.0) 9 (22.0) 0.055
> 65 42 (50.6) 39 (92.9) 3 (7.1)  
Sex
Male 28 (33.7) 23 (82.1) 5 (17.9) 0.530
Female 55 (66.3) 48 (87.3) 7 (12.7)  
Tumor location
Head 52 (62.7) 43 (82.7) 9 (17.3) 0.142
Neck 6 (7.2) 6 (100.0) 0 (0.0)  
Body 4 (4.8) 2 (50.0) 2 (50.0)  
Tail 6 (7.2) 6 (100.0) 0 (0.0)  
Uncinate 10 (12.0) 10 (100.0) 0 (0.0)  
Others 5 (6.0) 4 (80.0) 1 (20.0)  
Tumor size, cm
≤ 3 47 (56.6) 40 (85.1) 7 (14.9) 0.897
> 3 36 (43.4) 31 (86.1) 5 (13.9)  
Tumor grade
Poorly differentiated 17 (20.5) 16 (94.1) 1 (5.9) 0.466
Moderately differentiated 46 (55.4) 39 (84.8) 7 (15.2)  
Well differentiated 20 (24.1) 16 (80.0) 4 (20.0)  
Stage
I 9 (10.8) 7 (77.8) 2 (22.2) 0.733
II 69 (83.1) 59 (85.5) 10 (14.5)  
III 4 (4.8) 4 (5.6) 0 (0.0)  
IV 1 (1.2) 1 (100.0) 0 (0.0)  
Recurrence status
Absent 22 (26.5) 18 (81.8) 4 (18.2) 0.562
Present 61 (73.5) 53 (86.9) 8 (13.1)  
Metastatic status
Absent 39 (47.0) 32 (82.1) 7 (17.9) 0.395
Present 44 (53.0) 39 (88.6) 5 (11.4)  
CA199
< 37U/ml 14 (16.9) 12 (85.7) 2 (14.3) 0.987
> 37U/ml 63 (75.9) 54 (85.7) 9 (14.3)